![]() |
|
|
Vol. 291, Issue 2, 531-537, November 1999
Program in Neurobiology and Behavior (E.H.C.) and Departments of
Psychiatry and Behavioral Science and Pharmacology (R.P.W., D.M.D.),
University of Washington, Seattle, Washington
Acute blockade of dopamine D2 receptors by the typical
antipsychotic drug haloperidol leads to alterations in neuronal gene expression and behavior. In the dorsolateral striatum, the levels of
mRNA for the immediate-early gene c-fos and the
neuropeptide gene neurotensin/neuromedin N (NT/N) are significantly
increased by haloperidol. An acute behavioral response to haloperidol
is catalepsy, considered to be a rodent correlate of some of the immediate extrapyramidal motor side effects seen in humans. Several lines of evidence suggest a link between neurotensin induction in the
dorsolateral striatum and catalepsy. We hypothesize that both striatal
gene induction and catalepsy elicited by haloperidol arise from the
combined effect of excitatory adenosinergic and glutamatergic inputs
acting at adenosine A2A and
N-methyl-D-aspartate (NMDA) receptors,
respectively. In agreement with our previous reports, adenosine
antagonists reduced haloperidol-induced c-fos and
neurotensin gene expression as well as catalepsy. In agreement with
other reports, the noncompetitive NMDA receptor antagonist MK-801 also
reduced gene expression and catalepsy in response to haloperidol. The
competitive NMDA receptor antagonist LY235959 decreased
haloperidol-induced catalepsy. We show here that blocking both
A2A and NMDA receptors simultaneously in conjunction with haloperidol resulted in a combined effect on gene expression and behavior that was greater than that for block of either receptor alone.
Both c-fos and NT/N mRNA levels were reduced, and
catalepsy was completely abolished. These results indicate that the
haloperidol-induced increases in c-fos and NT gene
expression in the dorsolateral striatum and catalepsy are driven
largely by adenosine and glutamatergic inputs acting at A2A
and NMDA receptors.
This article has been cited by other articles:
![]() |
K. Hattori, S. Uchino, T. Isosaka, M. Maekawa, M. Iyo, T. Sato, S. Kohsaka, T. Yagi, and S. Yuasa Fyn Is Required for Haloperidol-induced Catalepsy in Mice J. Biol. Chem., March 17, 2006; 281(11): 7129 - 7135. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Viyoch, N. Matsunaga, M. Yoshida, H. To, S. Higuchi, and S. Ohdo Effect of Haloperidol on mPer1 Gene Expression in Mouse Suprachiasmatic Nuclei J. Biol. Chem., February 25, 2005; 280(8): 6309 - 6315. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Dobner, J. Fadel, N. Deitemeyer, R. E. Carraway, and A. Y. Deutch Neurotensin-deficient mice show altered responses to antipsychotic drugs PNAS, June 20, 2001; (2001) 141042198. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Dobner, J. Fadel, N. Deitemeyer, R. E. Carraway, and A. Y. Deutch Neurotensin-deficient mice show altered responses to antipsychotic drugs PNAS, July 3, 2001; 98(14): 8048 - 8053. [Abstract] [Full Text] [PDF] |
||||